Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Damijan Valentinuzzi"'
Autor:
Damijan Valentinuzzi, Ivana Zagar, Robert Jeraj, Jens C. Eickhoff, U Simoncic, Nina Boc, Ziga Zupancic, Andrej Studen, Martina Vrankar, Valentina Ahac, Katja Skalic, Mojca Unk
Publikováno v:
Radiology and Oncology, Vol 54, Iss 3, Pp 285-294 (2020)
Radiology and Oncology
Radiology and Oncology
Background Immune checkpoint inhibitors have changed the paradigm of cancer treatment; however, non-invasive biomarkers of response are still needed to identify candidates for non-responders. We aimed to investigate whether immunotherapy [18F]FDG PET
Autor:
Robert Jeraj, U Simoncic, Maja Čemažar, Katja Ursic, Damijan Valentinuzzi, Simon Bucek, Gregor Sersa, Martina Vrankar, Matea Maruna
Publikováno v:
The Physics of Cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::620a747fa290f1c0ba3c17e52e33613f
https://doi.org/10.1142/9789811223495_0007
https://doi.org/10.1142/9789811223495_0007
Publikováno v:
Cancer Research. 81:227-227
Introduction: Treatment resistance contributes importantly to clinical response of metastatic prostate cancer (mPC) patients. We hypothesize that patients with more resistant lesions would lead to more unfavorable treatment response. The goal of this
Autor:
Damijan Valentinuzzi, Robert Jeraj
Publikováno v:
Physics in Medicine & Biology. 65:24TR01
Modern cancer immunotherapy has revolutionised oncology and carries the potential to radically change the approach to cancer treatment. However, numerous questions remain to be answered to understand immunotherapy response better and further improve
Autor:
Martina Vrankar, Damijan Valentinuzzi, Matea Maruna, Maruša Turk, Maja Cemazar, Robert Jeraj, Urban Simoncic, Gregor Sersa, Katja Ursic
Publikováno v:
Cancer Immunology Research. 8:A09-A09
Immune checkpoint inhibitors have shown impressive benefits for patients with various types of cancer. However, patients who respond are still a minority. To improve the response rates, combinations of various immunotherapies, as well as combinations
Publikováno v:
Physics in Medicine & Biology. 64:115001
Metastatic cancer patients invariably develop treatment resistance. Different levels of resistance lead to observed heterogeneity in treatment response. The main goal was to evaluate treatment response heterogeneity with a computation model simulatin
Publikováno v:
Physics in Medicine & Biology. 64:025017
Cancer immunotherapy is a rapidly developing field, with numerous drugs and therapy combinations waiting to be tested in pre-clinical and clinical settings. However, the costly and time-consuming trial-and-error approach to development of new treatme
Publikováno v:
Cancer Immunology Research. 5:B73-B73
Cancer treatment with combination of radiotherapy (RT) and immunotherapy (IT) (immune check-point inhibitors) has gained promising results in preclinical and clinical studies. Accumulating evidence suggests that RT is beneficial not only because of i
Publikováno v:
Medical Physics. 41:435-435
Purpose: Patient response to anti-angiogenic therapies with vascular endothelial growth factor receptor - tyrosine kinase inhibitors (VEGFR TKIs) is heterogeneous. This study investigates key biological characteristics that drive differences in patie
Publikováno v:
Physics in Medicine & Biology; Jun2019, Vol. 64 Issue 11, p1-1, 1p